GEN Exclusives

More »

GEN News Highlights

More »
Jun 20, 2007

Greenovation Biotech Granted U.S. Patent on Plant-Based Glyco-Engineering

  • Greenovation Biotech reports that the company received its first U.S. patent in the area of plant-based glyco-engineering. This patent offers wide-ranging protection for the targeted processing of a plant-specific sugar residue.

    Scientists at greenovation Biotech have been working on improvements in biopharmaceuticals through glyco-engineering by designing production strains in moss. Through specific genetic modifications of the expression system, such as knockouts and the over-expression of glycosyltransferases, the sugar structures of the produced proteins could be adapted to those of human beings.

    “The U.S. pharmaceuticals market is by far the market with the strongest turnover,” Gilbert Gorr, CSO, notes . “For this reason the granting of this patent is very significant for mapping out the future direction for our company.” greenovation Biotech believes that the U.S. patent will enable the company to build on its position as a manufacturer of therapeutic glycoproteins in plants.



GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »